Workspace of Experimental Anesthesiology 

Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

Open Menu
Blick über die rechte Schulter eines Forschers, der mit einer langen Pipette eine Flüssigkeit in ein kleines Glasgefäß füllt.

Pain Research Focus

Our group is interested in mechanisms of pathological (clinical) pain and its inhibition by opioids outside the central nervous system (CNS). This can be achieved by activation of opioid receptors on peripheral sensory neurons and immune cells within injured tissue by exogenous or endogenous opioids. The latter (endorphins, enkephalins) are produced by immune cells infiltrating inflamed tissue. Activation of such cells by stressful stimuli or releasing agents (corticotropin-releasing factor, catecholamines, cytokines, chemokines, bacterial components) releases the opioids and ameliorates pain.

It is important to understand and exploit these mechanisms, since there is an urgent need for new medications. This is because of the detrimental side effects produced by currently available drugs, such as gastrointestinal ulcers, bleeding, and heart attacks caused by nonsteroidal analgesics (COX inhibitors), or nausea, constipation, respiratory depression, and addiction produced by morphine-like drugs acting on opioid receptors in the CNS. Clinical pain is almost always associated with inflammation, as in surgery, arthritis, cancer, inflammatory bowel disease, or neuropathic pain (e.g., caused by amputation).

Inflammation leads to accumulation of opioid-producing immune cells as well as upregulation, enhanced axonal transport, and increased G-protein coupling of opioid receptors on peripheral sensory neurons. These mechanisms offer a promising strategy for the development of new analgesic medications without CNS adverse effects. We use molecular, histological, biochemical, electrophysiological, and behavioral methods combined with nanochemistry, mathematical modeling, and clinical studies in patients.

Our laboratory features molecular, biochemical, cellular, electrophysiological, and behavioral methods. Clinical studies are performed in our pain clinic, perioperative setting, and intensive care unit. We are funded by the German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), and European Union. We mentor Bachelor, Masters, PhD, and MD students.

Opioid peptide-containing circulating leukocytes extravasate upon activation of adhesion molecules (e.g., ICAM-1; beta2 integrin). Corticotropin-releasing factor (CRF), chemokines or noradrenaline (NA, released from sympathetic neurons) can elicit opioid release by activating their respective receptors (CRF receptors, CRFR; adrenergic receptors, AR) on leukocytes. Exogenous opioids (EO) or endogenous opioid peptides (OP, green triangles) bind to opioid receptors (OR) that are synthesized in dorsal root ganglia and transported along intraaxonal microtubules to peripheral (and central) terminals of sensory neurons. The subsequent inhibition of excitatory ion channels (e.g., TRPV1, Ca2+) and of substance P (sP) release results in pain inhibition.